This Document Is the Accepted Manuscript Version of a Published Work That Appeared in Final Form in ACS Chemical Neuroscience, Copyright © American
This document is the Accepted Manuscript version of a Published Work that appeared in final form in ACS Chemical Neuroscience, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see http://pubs.acs.org/doi/abs/10.1021/acschemneuro.5b00107 The pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB- PINACA, 5F-ADB-PINACA, ADBICA and 5F-ADBICA Samuel D. Banister,a,b Michael Moir,b Jordyn Stuart,c Richard C. Kevin,d Katie E. Wood,d Mitchell Longworth,b Shane M. Wilkinson,b Corinne Beinat,a,b Alexandra S. Buchanan,e,f Michelle Glass,g Mark Connor,c Iain S. McGregor,d Michael Kassioub,h* aDepartment of Radiology, Stanford University School of Medicine, Stanford, CA 94305, USA; bSchool of Chemistry, The University of Sydney, NSW 2006, Australia; cFaculty of Medicine and Health Sciences, Macquarie University, NSW 2109, Australia; dSchool of Psychology, The University of Sydney, NSW 2006, Australia; eCenter for Immersive and Simulation-based Learning, Stanford University School of Medicine, Stanford, CA 94305, USA; fDepartment of Anaesthesia, Prince of Wales Hospital, Randwick, NSW 2031, Australia; gSchool of Medical Sciences, The University of Auckland, Auckland 1142, New Zealand; hFaculty of Health Sciences, The University of Sydney, NSW 2006, Australia. Keywords: cannabinoid, THC, JWH-018, FUBINACA, PINACA 1 Abstract: Synthetic cannabinoid (SC) designer drugs based on indole and indazole scaffolds and featuring L-valinamide or L-tert-leucinamide side-chains are encountered with increasing frequency by forensic researchers and law enforcement, and are associated with serious adverse health effects.
[Show full text]